114 related articles for article (PubMed ID: 17923099)
1. A miniaturized high-throughput screening assay for fucosyltransferase VII.
Ahsen Ov; Voigtmann U; Klotz M; Nifantiev N; Schottelius A; Ernst A; Müller-Tiemann B; Parczyk K
Anal Biochem; 2008 Jan; 372(1):96-105. PubMed ID: 17923099
[TBL] [Abstract][Full Text] [Related]
2. Measurement of alpha(1-3) fucosyltransferase activity using scintillation proximity.
Hood CM; Kelly VA; Bird MI; Britten CJ
Anal Biochem; 1998 Jan; 255(1):8-12. PubMed ID: 9448836
[TBL] [Abstract][Full Text] [Related]
3. Significant decrease in alpha1,3-linked fucose in association with increase in 6-sulfated N-acetylglucosamine in peripheral lymph node addressin of FucT-VII-deficient mice exhibiting diminished lymphocyte homing.
Hiraoka N; Petryniak B; Kawashima H; Mitoma J; Akama TO; Fukuda MN; Lowe JB; Fukuda M
Glycobiology; 2007 Mar; 17(3):277-93. PubMed ID: 17172261
[TBL] [Abstract][Full Text] [Related]
4. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
5. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of human alpha-1,3-fucosyltransferase V: glycosidic cleavage occurs prior to nucleophilic attack.
Murray BW; Wittmann V; Burkart MD; Hung SC; Wong CH
Biochemistry; 1997 Jan; 36(4):823-31. PubMed ID: 9020780
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput screening system for alpha1-3 fucosyltransferase-VII inhibitor utilizing scintillation proximity assay.
Miyashiro M; Furuya S; Sugita T
Anal Biochem; 2005 Mar; 338(1):168-70. PubMed ID: 15707950
[No Abstract] [Full Text] [Related]
8. Development of a sensitive separation and quantification method for sialyl Lewis X and Lewis X involving anion-exchange chromatography: biochemical characterization of alpha1-3 fucosyltransferase-VII.
Miyashiro M; Furuya S; Sugita T
J Biochem; 2004 Nov; 136(5):723-31. PubMed ID: 15632313
[TBL] [Abstract][Full Text] [Related]
9. A time-resolved immunofluorometric method for the measurement of sialyl Lewis x-synthesizing alpha1,3-fucosyltransferase activity.
Räbinä J; Smithers N; Britten CJ; Renkonen R
Anal Biochem; 1997 Mar; 246(1):71-8. PubMed ID: 9056185
[TBL] [Abstract][Full Text] [Related]
10. Highly sensitive cell-based assay system to monitor the sialyl Lewis X biosynthesis mediated by alpha1-3 fucosyltransferase-VII.
Miyashiro M; Furuya S; Fujishige K; Sugita T
Biochem Biophys Res Commun; 2004 Nov; 324(1):98-107. PubMed ID: 15464988
[TBL] [Abstract][Full Text] [Related]
11. Reaction mechanism and substrate specificity for nucleotide sugar of mammalian alpha1,6-fucosyltransferase--a large-scale preparation and characterization of recombinant human FUT8.
Ihara H; Ikeda Y; Taniguchi N
Glycobiology; 2006 Apr; 16(4):333-42. PubMed ID: 16344263
[TBL] [Abstract][Full Text] [Related]
12. FRET-based direct and continuous monitoring of human fucosyltransferases activity: an efficient synthesis of versatile GDP-L-fucose derivatives from abundant D-galactose.
Maeda T; Nishimura S
Chemistry; 2008; 14(2):478-87. PubMed ID: 17929334
[TBL] [Abstract][Full Text] [Related]
13. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay.
Meng T; Su HR; Binkert C; Fischli W; Zhou L; Shen JK; Wang MW
Acta Pharmacol Sin; 2008 Apr; 29(4):517-27. PubMed ID: 18358099
[TBL] [Abstract][Full Text] [Related]
14. Development of fucosyltransferase and fucosidase inhibitors.
Tu Z; Lin YN; Lin CH
Chem Soc Rev; 2013 May; 42(10):4459-75. PubMed ID: 23588106
[TBL] [Abstract][Full Text] [Related]
15. A High-Throughput Glycosyltransferase Inhibition Assay for Identifying Molecules Targeting Fucosylation in Cancer Cell-Surface Modification.
Zhang X; Chen F; Petrella A; Chacón-Huete F; Covone J; Tsai TW; Yu CC; Forgione P; Kwan DH
ACS Chem Biol; 2019 Apr; 14(4):715-724. PubMed ID: 30831024
[TBL] [Abstract][Full Text] [Related]
16. Assay concordance between SPA and TR-FRET in high-throughput screening.
von Ahsen O; Schmidt A; Klotz M; Parczyk K
J Biomol Screen; 2006 Sep; 11(6):606-16. PubMed ID: 16760369
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of bisubstrate analogues targeting alpha-1,3-fucosyltransferase and their activities.
Izumi M; Kaneko S; Yuasa H; Hashimoto H
Org Biomol Chem; 2006 Feb; 4(4):681-90. PubMed ID: 16467942
[TBL] [Abstract][Full Text] [Related]
18. Which aspects of HTS are empirically correlated with downstream success?
Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
[TBL] [Abstract][Full Text] [Related]
19. High-throughput identification of fucosyltransferase inhibitors using carbohydrate microarrays.
Bryan MC; Lee LV; Wong CH
Bioorg Med Chem Lett; 2004 Jun; 14(12):3185-8. PubMed ID: 15149672
[TBL] [Abstract][Full Text] [Related]
20. Lactose as affinity eluent and a synthetic sulfated copolymer as inhibitor, in conjunction with synthetic and natural acceptors, differentiate human milk Lewis-type and plasma-type alpha-L-fucosyltransferases.
Chandrasekaran EV; Rhodes JM; Jain RK; Matta KL
Biochem Biophys Res Commun; 1994 Jan; 198(1):350-8. PubMed ID: 8292040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
